Cytomegalovirus infection in transplant recipients. The role of tumor necrosis factor.
Human cytomegalovirus (CMV) infection is an important cause of morbidity and mortality in transplant recipients. CMV infection commonly results from the reactivation of a latent infection. Using a set of monoclonal anti-CMV antibodies, we found CMV antigen expression in peripheral blood mononuclear cells (PBMNC), particularly in monocytes, in 312 of 816 samples from 190 allograft recipients. The detection of CMV-IE antigens and CMV-IE DNA in PBMNC indicates that positive cells may represent truly infected cells. The relation between increased cytokine plasma levels (particularly following treatment by pan-T cell antibodies) and the appearance of CMV antigens in PBMNC suggests that cytokines may play an important role in the reversal of CMV latency. This hypothesis is supported by our finding that tumor necrosis factor-alpha (TNF) is able to stimulate the activity of the CMV-IE enhancer/promoter region in the human monocytic cell line, HL-60. The interleukins 1, 2, 3, 4, 6, 8 and 10; transforming growth factor-beta; interferongamma; and granulocyte/macrophage colony-stimulating factor did not show any enhancing effect on the CMV promoter activity. Thus, TNF-alpha seems to play a key role in regulating the balance between latency and reactivation of CMV infection. Inhibition of TNF-alpha release or action may be an alternative strategy for preventing CMV-associated morbidity in allograft recipients.
Fietze
E
E
Department of Immunology, Medical School (Charité) Humboldt University of Berlin, Germany.
Prösch
S
S
Reinke
P
P
Stein
J
J
Döcke
W D
WD
Staffa
G
G
Löning
S
S
Devaux
S
S
Emmrich
F
F
von Baehr
R
R
D000328:Adult; D000911:Antibodies, Monoclonal / Q000276:immunology; D000914:Antibodies, Viral / Q000276:immunology; D000956:Antigens, Viral / Q000032:analysis; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D002648:Child; D016207:Cytokines / Q000494:pharmacology; D003587:Cytomegalovirus / Q000235:genetics / Q000254:growth & development / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000209:etiology / Q000276:immunology*; D004279:DNA, Viral / Q000032:analysis; D006084:Graft Rejection / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects*; D007963:Leukocytes, Mononuclear / Q000821:virology; D016031:Liver Transplantation / Q000009:adverse effects*; D016853:Muromonab-CD3 / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000276:immunology; D014184:Transplantation, Homologous; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology; D014775:Virus Activation / Q000502:physiology
D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D000956:Antigens, Viral; D000961:Antilymphocyte Serum; D016207:Cytokines; D004279:DNA, Viral; D016853:Muromonab-CD3; D014409:Tumor Necrosis Factor-alpha